GME, or granulomatous meningoencephalomyelitis, is an inflammatory disease of the brain and spinal cord in dogs. It occurs when the immune system attacks the central nervous system, creating clusters of inflammatory cells that damage surrounding tissue. GME primarily affects small-breed dogs, with females more commonly diagnosed than males, and the average age of onset is around 4 years old.
What Happens in the Brain
In GME, certain white blood cells accumulate in the brain, spinal cord, or the membranes surrounding them. These cells form dense clusters called granulomas that press on and damage nervous tissue. The exact trigger remains unclear, but GME is classified as an autoimmune condition, meaning the dog’s own immune system is driving the inflammation rather than an infection.
GME falls under a broader category veterinary neurologists call meningoencephalomyelitis of unknown origin (MUE), which groups together several inflammatory brain diseases that look similar on diagnostic tests but differ under the microscope. Because a definitive GME diagnosis technically requires a tissue biopsy (often only obtained after death), most living dogs receive a presumptive diagnosis based on imaging, spinal fluid analysis, and their response to treatment.
Three Forms of GME
GME presents in three distinct patterns, and the form your dog has significantly affects how the disease behaves.
Focal GME produces a single mass-like lesion in one area of the brain or spinal cord. It tends to develop more slowly than other forms and can mimic a brain tumor on imaging. Dogs with focal GME often have symptoms that reflect the specific location of the lesion, such as seizures if the forebrain is affected or a head tilt if the balance centers are involved.
Disseminated GME is the most common and most aggressive form. Inflammatory lesions appear in multiple areas of the central nervous system simultaneously, causing a wider range of neurological problems that often come on suddenly and worsen quickly. Dogs with this form may show a combination of symptoms affecting different parts of the brain and spinal cord.
Ocular GME targets the optic nerves, leading to sudden vision loss, dilated pupils that don’t respond normally to light, and inflammation visible inside the eye. This form can occur on its own or alongside brain involvement.
Symptoms to Recognize
The signs of GME depend entirely on where the inflammation is located. In a review of 151 reported GME cases, the most frequently documented symptoms were loss of coordination (ataxia), cranial nerve problems affecting the face and eyes, seizures, and circling behavior. Many dogs also develop neck pain, fever, and a general decline in alertness.
When the forebrain is affected, dogs may have seizures, pace or wander aimlessly, press their head against walls, or walk in circles. Lesions in the midbrain can cause trembling, abnormal eye movements, and difficulty with vision. When the balance centers of the brain are involved, dogs typically tilt their head to one side, lose their balance, and develop rapid involuntary eye movements called nystagmus.
In the disseminated form, these symptoms can overlap and progress over days to weeks. Focal GME tends to produce a slower, more localized set of symptoms that develops over weeks to months.
Which Dogs Are Most at Risk
GME disproportionately affects small-breed dogs. Breeds commonly reported include toy poodles, Chihuahuas, Maltese, and terrier breeds, though it can occur in any breed, including French Bulldogs and other medium-sized dogs. The typical age of onset is around 3 to 5 years, though cases have been diagnosed in dogs ranging from puppyhood to old age. Females appear to be affected more often than males.
How GME Is Diagnosed
Veterinary neurologists typically reach a presumptive diagnosis using a combination of MRI and analysis of cerebrospinal fluid (the liquid surrounding the brain and spinal cord). On MRI, GME lesions may appear as single or multiple areas of abnormal tissue that enhance with contrast dye. In the focal form, the lesion can look remarkably like a tumor, making the distinction challenging.
Spinal fluid analysis usually shows an elevated white blood cell count, with certain immune cells predominating. This pattern helps differentiate GME from infections, which tend to produce a different cellular profile. Blood tests and infectious disease screening are also performed to rule out conditions like fungal infections, tick-borne diseases, or other causes of brain inflammation that can look identical to GME.
Interestingly, some dogs diagnosed with MUE have a normal-appearing MRI. A 2024 study in the Journal of Veterinary Internal Medicine found that dogs with no visible lesions on MRI had significantly better outcomes, with only 5% dying from their disease compared to 33% of dogs with abnormal MRI findings.
Treatment and What to Expect
GME treatment centers on suppressing the immune system to stop it from attacking the nervous system. The cornerstone medication is a corticosteroid (typically prednisone or prednisolone), which is started at a high dose and then gradually tapered. Most treatment protocols keep the steroid dose steady for the first three months before reducing it by about 25% every six to eight weeks, eventually reaching a much lower maintenance dose given every few days.
Because long-term steroid use carries significant side effects (increased thirst, weight gain, muscle weakness, susceptibility to infections), most neurologists add a second immunosuppressive drug to allow the steroid dose to come down faster. The two most common options are a chemotherapy-derived injectable given in cycles every few weeks, and an oral immune-suppressing medication taken daily. Both work by dialing down the overactive immune response through different mechanisms than steroids.
The injectable medication is typically given every three weeks for several cycles, with the interval gradually extended to every eight weeks. It may be continued long-term or eventually discontinued depending on how the dog responds. The oral option requires periodic blood level monitoring to make sure the drug stays within an effective range.
Side effects from immunosuppressive therapy vary. Steroids cause the most noticeable changes in daily life: your dog will likely drink and urinate more, feel hungrier, and may gain weight. The secondary medications can suppress bone marrow function, so regular blood work is part of ongoing monitoring.
Prognosis and Long-Term Outlook
The outlook for dogs with GME has improved considerably with modern immunosuppressive protocols. A large 2024 study found that median survival exceeded 107 months (nearly 9 years) in dogs treated for MUE, regardless of whether their MRI showed visible lesions. That said, outcomes vary widely depending on the form of GME and how the individual dog responds to treatment.
Dogs with disseminated GME that progresses rapidly tend to have a more guarded prognosis, especially if they don’t respond to initial therapy within the first few weeks. Dogs with focal GME or those whose MRI appears normal generally do better. The study found that having an abnormal MRI carried roughly 7.7 times the risk of dying from the disease compared to having a normal MRI.
Relapses are common and can occur when medications are tapered too quickly or sometimes even on stable doses. A relapse typically looks like a return or worsening of the original neurological symptoms. When this happens, the treatment team will usually increase medication doses temporarily and slow the tapering schedule. Some dogs require lifelong therapy at a low maintenance dose, while others can eventually be weaned off treatment entirely. The decision to stop medication is made individually, based on how long the dog has been stable and how they respond to each dose reduction.